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ABSTRACT Acquired immunodeficiency syndrome pa-
tients are frequently coinfected with Epstein-Barr virus
(EBV). In this report, we demonstrate that an EBV immedi-
ate-early gene product, BamHI MLF1, stimulates expression
of the bacterial chloramphenicol acetyltransferase (CAT) gene
linked to the human immunodeficiency virus (EHV) promoter.
The HIV promoter sequences necessary for trans-activation by
EBV do not include the tat-responsive sequences. In addition,
in contrast to the other herpesvirus trans-activators previously
studied, the EBV BamHI MLF1 gene product appears to
function in part by a posttranscriptional mechanism, since it
increases pHIV-CAT protein activity more than it increases
HIV-CAT mRNA. This ability of an EBV gene product to
activate HIV gene expression may have biologic consequences
in persons coinfected with both viruses.
Although it is estimated that up to one million people in the
United States are infected with the human immunodefi-
ciency virus (HIV), only a portion of the infected persons
develop acquired immunodeficiency syndrome (AIDS). At
present, we do not understand the factors that may differ-
entiate those HIV-infected individuals in whom active AIDS
will develop from those who will remain only latently
infected. One possibility is that other viruses may act as
cofactors with HIV in producing disease.
An interesting mechanism whereby two viruses might
interact at the molecular level is promoter trans-activation.
HIV has a single promoter in the 5' long terminal repeat
sequence of the proviral genome (1, 2), which is stimulated
in trans by the HIV-encoded trans-acting transcriptional
activator (tat) (3, 4). HIV DNA sequences located 3' of the
mRNA start site are necessary for trans-activation by tat.
Recently, it has been reported that a herpes simplex type I
gene product can increase the expression of a heterologous
gene linked to the HIV promoter (5, 6). In addition, several
other DNA viruses, including three papovaviruses (JC, BK,
and lymphotropic papovaviruses) also trans-activate the
HIV promoter (6). These DNA virus trans-activators all
function by increasing the level of HIV promoter-directed
mRNA. In contrast, the mechanism by which tat itself
activates HIV gene expression has been somewhat contro-
versial. Some reports indicate that the trans-activation by tat
can be explained totally by increased levels of mRNA,
whereas other reports find greater stimulation at the protein
level than can be accounted for by the observed increase in
HIV-directed mRNA alone (7-11).
Because of the very high frequency of Epstein-Barr virus
(EBV) infection in AIDS patients, with up to 96% showing
serologic evidence of active infection (12), we have investi-
gated whether EBV functions might also activate the HIV
promoter. EBV is a human B-cell lymphotropic virus that is
the etiologic agent of infectious mononucleosis. EBV also
induces fatal B-cell lymphomas in immunocompromised
patients (13) and is associated with both Burkitt lymphoma
and nasopharyngeal carcinoma (14, 15). Homosexual men,
one of the main groups at risk for HIV infection, have a 50%
prevalence of active EBV infection (EBV early antigen,
21:40) even when seronegative for HIV, whereas in healthy
heterosexuals the prevalence of active EBV infection is only
5% (16).
We have examined the ability of two different EBV imme-
diate-early gene products, BamHI MLFI and BamHI ZLFJ,
to trans-activate the HIV promoter. We report here that the
EBV gene product BamHI MLFJ stimulates expression of the
bacterial chloramphenicol acetyltransferase (CAT) gene
linked to the HIV promoter, whereas the BamHI ZLFJ gene
product does not. We show that the HIV promoter sequences
necessary for trans-activation by BamHI MLFJ are different
from those required for tat trans-activation. In addition, we
demonstrate that the EBV trans-activator, BamHI MLF1,
increases pHIV-CAT activity disproportionately at the pro-
tein level, suggesting at least in part a posttranscriptional
mechanism of trans-activation. The BamHI MLFJ EBV
trans-activator thus appears to function by a mechanism
different from that of other DNA viruses.
METHODS
Cell Lines. The experiments were all performed in an
EBV-negative human Burkitt lymphoma B-cell line (B-JAB)
and an EBV-positive Burkitt lymphoma B-cell line (AG876).
Lymphoid cell lines were maintained in RPMI media with
10% fetal calf serum.
DNA Transfection. Plasmid DNA was purified through two
sequential cesium chloride gradients. Electroporation into
lymphoid cells was accomplished by using a "Zapper"
electroporation unit from the University of Wisconsin med-
ical electronics shop at 1500 V.
Plasmid Constructions. EBV plasmids. Two EBV trans-
activating plasmids were constructed. The plasmid pEBV-
MIE places the second exon of the EBV immediate-early
gene, BamHI MLFJ, under the control of the cytomegalo-
virus (CMV) immediate-early promoter. Other investigators
(17) have shown that only the second exon of the BamHI
MLFI gene product is required for trans-activation effects.
To construct pEBV-MIE, the EBV DNA sequence from
positions 81,253-84,238 (18) was excised from a vector
containing the EBV Bgl II J fragment (19) (a gift from Georg
Bornkamm, University of Freiburg, Freiburg, F.R.G.) and
then ligated into the vector phD1013 (a gift from Michelle
Davis and E. S. Huang, University of North Carolina,
Abbreviations: AIDS, acquired immunodeficiency syndrome; HIV,
human immunodeficiency virus; EBV, Epstein-Barr virus; CMV,
cytomegalovirus; CAT, chloramphenicol acetyltransferase.
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FIG. 1. Construction of pEBV-MIE. The EBV DNA from
sequences 81,253-84,238 (18) was excised from the Bgl II J fragment
of the EBV genome, then ligated into the BamHI site of the phD1013
vector (a gift from Michelle Davis and E. S. Huang), which has the
human CMV immediate-early promoter. The pEBV-MIE thus con-
tains the second exon of the EBV immediate-early gene product,
BamHI MLFJ, under the control of the CMV immediate-early gene
promoter.
Chapel Hill, NC), under the control of the CMV promoter
(Fig. 1). In a second plasmid, pEBV-ZIE, the EBV imme-
diate-early gene product located within the BamHI Z frag-
ment of the genome, was placed under control of the CMV
immediate-early gene promoter in phD1013.
HIV-CAT plasmids. Two HIV-CAT plasmids were con-
structed. The pHIV-CAT plasmid contains the intact HIV
promoter, including the tat-responsive region, linked to the
bacterial CAT gene (Fig. 2). The second plasmid, pHIV
ACAT, is identical to pHIV-CAT except that the HIV TAR
sequences from + 29 to + 77 (relative to the mRNA start
site) have been deleted, so the resultant plasmid is no longer
responsive to trans-activation by tat.
HIV tat plasmids. Two different tat-expressing plasmids
were tested. The plasmid pBenn-2 (a gift from Malcolm
Martin, National Institute of Allergy and Infectious Dis-
9
FIG. 3. Effect of the EBV BamHI Z immediate-early gene
product on pHIV-CAT. Five micrograms of the pHIV-CAT plas-
mid was cotransfected into the EBV-positive AG876 cell line with
either 5 Ag of phD1013 vector DNA, or with 5 ,ug of the pEBV-ZIE
plasmid. CAT activity was measured from cell extracts 48 hr after
transfection. The CAT activity of pHIV-CAT was not affected by
cotransfection with the EBV BamHI Z immediate-early gene prod-
uct. The M-CAT plasmid, which has an EBV early promoter
(BMLF1) fused to the CAT gene, is trans-activated by the pEBV-
ZIE plasmid in AG876 cells and serves as the positive control.
eases, Bethesda, MD) (20) contains the portion of the HIV
genome from the 5' long terminal repeat through nucleotide
8052. The phD101-tat plasmid (a gift from Michelle Davis
and E. S. Huang) contains the HIV sequences from posi-
tions 5331-8052 under the control of the CMV immediate-
early promoter. Neither plasmid encodes a functional art
gene product.
CAT Assays. Five micrograms of the pHIV-CAT plasmid
DNA was cotransfected with either 5 ,ug of phD1013 DNA or
with S ,ug of the test plasmid. Forty-eight hours after
transfection, an extract of the cells was prepared and incu-
bated at 370C with [14C]chloramphenicol in the presence of
acetyl coenzyme A, as described (21). The percentage acet-
ylation of chloramphenicol was quantitated by thin-layer
chromatography followed by autoradiography and scintilla-
tion counting. All CAT assays were repeated with smaller
amounts of extract if results were not in the linear range
(<50% chloramphenicol acetylation).
RNA Analysis. Total cellular RNA was prepared 2 days
after transfection by a modification of the Favaloro method
(22, 23). A 700-base-pair (bp) DNA fragment containing the
HIV promoter plus 250 bp of the CAT gene was excised from
pHIV-CAT and cloned into the pGem 2 vector (Promega),
which has the SP6 promoter. Total cellular RNA (35 Ag) was
hybridized overnight to a complementary 32P-labeled single-
stranded RNA probe (6.5 x 104 cpm) generated by SP6
polymerase. The hybrid probe was then digested with S1
nuclease (24) and the S1 nuclease-protected fragment was
electrophoresed on a 6% acrylamide gel with 7 M urea.
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FIG. 2. Construction of pHIV-CAT and
+77(HINDM) pHIVA&CAT. The pHIV-CAT plasmid containsthe intact HIV promoter sequences (-342 to
+ 77 relative to the mRNA start site), linked to
the bacterial CAT gene. The pHIVACAT is
+ 29 (SST - I) identical to pHIV-CAT except that the HIVtat-responsive sequences (TAR) from + 29 to
CA3 E--3 + 77 have been deleted.
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FIG. 4. Effect of the EBV BamHI M immediate-early gene
product on pHIV-CAT. Five micrograms of the pHIV-CAT was
cotransfected into EBV-negative B-JAB cells with either 5 gg of
pEBV-MIE or 5 gg of pBenn-2 (a tat-producing plasmid) and CAT
activity was measured 48 hr later. Both the pEBV-MIE and the
pBenn-2 plasmids increase the CAT activity of pHIV-CAT, al-
though the degree of trans-activation produced by pBenn-2 is
greater than that observed with pEBV-MIE. In the experiment
shown, 5 All (of a total of 200 Al) of the extract was incubated at 370C
for 1 hr. Under these conditions, pHIV-CAT by itself produced
0.3% acetylation, whereas the sample cotransfected with pEBV-
MIE produced 9.7% acetylation, and the sample cotransfected with
the pBenn-2 plasmid produced 51.3% acetylation.
RESULTS
The EBV BamIlI Z Immediate-Early Gene Product Does Not
Affect pHIV-CAT Activity. Two different EBV immediate-
early gene products were tested for the ability to stimulate the
activity of the pHIV-CAT plasmid. When the electroporation
technique was used to introduce plasmid DNA into B-JAB
cells, the baseline activity produced by pHIV-CAT alone was
significantly higher than that produced by the negative control
plasmid pCAT3M. Incubating 100 ,l (of a total of 200 ,u1) of
the pHIV-CAT extract for 1 hr at 37°C generally resulted in
20-50%o acetylation, whereas <1% acetylation was produced
by the same amount of pCAT3M extract. Therefore, the
cotransfection experiments were generally performed with
only a small amount (5-20 ,ul) of the total 200-,u extract so
that the CAT activity of the conditions cotransfected with
active transactivators remained within the linear range. Al-
though the transfection efficiency varied from experiment to
experiment, within each experiment the CAT activity pro-
duced by duplicate transfections was very similar (coefficient
of variation averaged 8.7%).
The Bam HI Z immediate-early gene product has been
shown (25, 26) to disrupt viral latency when transfected into
the latently EBV-infected Raji cells. In this laboratory, co-
transfection of the BamHI Z immediate-early gene product
(plasmid pEBV-ZIE) into an EBV-infected cell line (AG876)
with different EBV promoters linked to the CAT gene pro-
duces increased CAT activity from two different early EBV
promoters but does not affect the activity of several latent
EBV promoters (S.K., unpublished data). The pHIV-CAT
activity was not affected by cotransfection with the BamHI Z
immediate-early gene in either EBV-positive or -negative cell
lines (Fig. 3). Therefore, the EBV BamHI Z immediate-early
gene product does not appear to stimulate HIV expression.
The EBV BamHI M Immediate-Early Gene Product Stim-
ulates Activity from the pHIV-CAT Plasmid. The second
EBV gene tested for potential of trans-activating pHIV-CAT
was the BamHI MLFJ immediate-early gene product
(plasmid pEBV-MIE). This EBV gene product has been
previously shown to trans-activate several different hetero-
logous promoters (17, 27) but, unlike the BamHI Z immedi-
ate-early gene product, does not disrupt viral latency when
transfected into the latently EBV-infected Raji cell line (26).
Fig. 4 shows the results of cotransfection experiments with
pEBV-MIE and pHIV-CAT. As expected, the activity of
pHIV-CAT, which contains the intact HIV promoter plus
the tat-responsive sequences, is dramatically increased
when cotransfected with the tat-producing plasmid pBenn-2.
The plasmid pEBV-MIE also reproducibly increases CAT
activity when cotransfected with pHIV-CAT (5- to 30-fold in
seven separate experiments; P < 0.05 by the Wilcoxin
signed-rank test). The phD1013 vector alone has no effect on
pHIV-CAT activity. Thus, pEBV-MIE encodes a trans-
activator capable of stimulating pHIV-CAT expression. The
pEBV-MIE effectively trans-activated pHIV-CAT in all cell
lines tested (HeLa, baby hamster kidney cells, Raji) (data
not shown). The effect of cotransfecting both the pBenn-2
and pEBV-MIE plasmids with pHIV-CAT was additive.
The EBV Trans-Activating Effect Does Not Require the HIV
TAR Sequences. The HIV tat gene does not increase pHIV-
CAT activity unless the tat-responsive sequence, located 3' of
the mRNA start site, is present. We tested the ability of the
EBV immediate-early gene product to stimulate CAT activity
from the HIV promoter when the tat-responsive sequence
(TAR) is deleted. Fig 5 shows the results of cotransfection
experiments using the pHIVACAT plasmid, which contains
the HIV promoter without the tat-responsive sequence. The
pHIVA&CAT plasmid, as expected, is not stimulated by co-
transfection with the pBenn-2 plasmid (which encodes tat).
However, the EBV trans-activator in plasmid pEBV-MIE
still stimulates CAT activity from pHIVACAT. The activity of
the CAT gene alone, with no HIV promoter elements, is not
significantly increased by cotransfection with pEBV-MIE
(data not shown). Therefore, the EBV and HIV trans-
activators require different HIV sequences for their effect and
may function through a different mechanism.
EBV Trans-Activates pHIV-CAT by a Posttranscriptional
Mechanism. We analyzed the ability of the HIV tat and EBV
BamHI MLFJ trans-activators to increase the steady-state
level of HIV long terminal repeat-directed mRNA. The
pHIV-CAT mRNA was quantitated by hybridizing 35 ,g of
total cellular RNA to a 32P-labeled single-stranded RNA
probe and then digesting with S1 nuclease. Only those
experiments that showed a similar amount of actin mRNA
(determined by RNA blot analysis) in each sample of har-
vested RNA were used for quantitation of pHIV-CAT
mRNA with S1 nuclease (data not shown).
Table 1 compares the effect of the different trans-
activating plasmids on the level of CAT activity versus the
increase in pHIV-CAT mRNA. Note that cotransfection
with the pEBV-MIE plasmid always resulted in an increased
level of pHIV-CAT mRNA; therefore, the trans-activating
effect must occur at least partly at the level of mRNA.
However, the observed increase in pHIV-CAT mRNA
could account for only 14-33% of the increase in CAT
activity. This suggests that the EBV BamHI MLFI gene
product may have more than one mechanism of trans-
activation, with at least one of these mechanisms occurring
at the posttranscriptional level.
Two different plasmids were used to test the mechanism of
the HIV tat trans-activator, and, somewhat surprisingly, the
two plasmids gave different results. Cotransfection with the
plasmid pBenn-2, which contains the tat gene product di-
rected by its own promoter, stimulated pHIV-CAT mRNA to
a similar degree as CAT activity. On the other hand, cotrans-
fection with the phD101-tat plasmid, which has tat under the
control of the CMV promoter, always produced significantly
more CAT activity than explained by the observed increase in
pHIV-CAT mRNA alone. These data suggest that subtle
differences in the level of tat expression may influence the
degree to which trans-activation occurs at the RNA versus
protein level. As only one vector (pEBV-MIE) was used to
determine the effect of the EBV trans-activator on pHIV-
Proc. Natl. Acad. Sci. USA 85 (1988)
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FIG. 5. The HIV tat-responsive sequences are not necessary for
trans-activation by pEBV-MIE. The pHIVACAT plasmid, which
has the tat-responsive sequence deleted, was cotransfected into
B-JAB cells with either pEBV-MIE or pBenn-2. The pEBV-MIE
still increases the CAT activity of pHIVACAT, whereas the tat-
producing pBenn-2 plasmid no longer trans-activates. In the exper-
iment shown, 20 Al of the extract was incubated at 37°C for 1 hr. The
pHIVACAT alone produced 2.7% acetylation, the pHIVACAT
cotransfected with pEBV-MIE produced 33.4% acetylation, and
pHIVACAT cotransfected with pBenn-2 produced 2.8% acetylation.
CAT, we cannot comment on whether different levels of this
trans-activator might similarly affect the degree of RNA
versus protein stimulation.
Fig. 6 shows the results of a representative S1 nuclease
experiment. In this particular experiment, cotransfection with
the pEBV-MIE plasmid produced a 29-fold increase in CAT
activity, whereas the mRNA increase (as measured by laser
densitometry) was only 4-fold. In the same experiment, the
cotransfection with the pBenn-2 plasmid resulted in a similar
degree of stimulation at both the mRNA and CAT levels.
DISCUSSION
We demonstrate that an EBV immediate-early gene product,
BamHI MLFJ, can activate the expression of a heterologous
gene linked to the HIV promoter. In addition, we show that
the trans-activating function of this EBV BamHI M imme-
diate-early gene product appears to occur, at least partly, at
the posttranscriptional level, since the degree of mRNA
stimulation observed cannot account for the level of protein
stimulation produced. The molecular interaction between
EBV and HIV suggested by our observations may have
biologic significance since both EBV and HIV can coinfect B
cells in patients with AIDS (28).
The function of the BamHI MLFJ gene product within
EBV-infected cells is not clearly understood. We have
shown that a number of different EBV promoters, including
that of the BamHI MLFI gene itself, are trans-activated by
the BamHI MLFJ gene product (29). In addition, the EBV
BamHI MLFJ gene product can trans-activate other promot-
ers, including the simian virus 40 early promoter and the
herpes simplex thymidine kinase gene promoter (17, 27). The
Sp6 CAT HIV
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FIG. 6. RNA analysis. Total cellular RNA (35 gg) was hybrid-
ized overnight to a 700-bp complementary 32P-labeled single-
stranded RNA probe produced by SP6 polymerase. The RNA
hybrid was then digested with S1 nuclease, and the protected
fragment was electrophoresed on a 6% acrylamide/7 M urea gel.
The expected protected fragment is 360 bp. The autoradiograph
shown is from Table 1, Exp.1. In this experiment, pHIV-CAT was
stimulated at the level ofCAT activity 29-fold by cotransfection with
pEBV-MIE and 151-fold by cotransfection with pBenn-2. Densi-
tometry analysis showed a 4-fold increase in the level of pHIV-CAT
mRNA after cotransfection with pEBV-MIE, and a .100-fold
increase in mRNA after cotransfection with pBenn-2. The quantita-
tive mRNA value for each band shown was arrived at by first
normalizing the densitometry value of each band to another band on
the same gel (data not shown) of intermediate intensity after short
and long autoradiographic exposures of the gel.
BamHI MLF1 gene might thus play a role in EBV analogous
to that of the herpes simplex immediate-early 110-kDa pro-
tein, which serves as a general trans-activator for a number of
different herpes simplex virus promoters (30) and has also
recently been shown to activate the HIV promoter (31).
A major distinction, however, between these two herpes-
virus trans-activators is that the herpes simplex virus imme-
diate-early 110-kDa protein trans-activating function appears
to occur primarily at the level of increased mRNA (5, 31),
whereas the EBV BamHI MLFI increases pHIV-CAT pro-
tein activity out of proportion to the increase induced at the
level of pHIV-CAT mRNA. In collaboration with E.-S.
Huang, we have recently found that a gene product of the
human CMV major immediate-early gene region also trans-
activates the pHIV-CAT plasmid (32). The CMV immediate-
early gene trans-activator, like that of herpes simplex virus
Table 1. Stimulation of RNA versus CAT activity by the HIV tat and EBV BamHI M immediate-early gene product
Acetylation, %
Trans-activating Extract used, pHIV-CAT pHIV-CAT plus CAT RNA
plasmid Exp. /II alone trans-activator stimulation stimulation CAT/RNA
pEBV-MIE 1 5 0.34 9.74 29 x 4 x 7.3
2 5 1.32 11.75 9 x 3 x 3.0
3 20 5.16 27.91 5 x 1.5 x 3.3
pBenn-2 1 5 0.34 51.3 151 x >100 x <1.5
2 2 0.16 16.05 100 x >100 x '1.0
phD101-tat 1 5 1.35 33.35 25 x 8 x 3.2
2 5 1.32 24.50 19 x 3 x 6.3
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1, operates entirely at the level of increased mRNA. Thus,
although the EBV BamHI MLF1 gene product resembles the
herpes simplex virus and CMV immediate-early genes in its
ability to stimulate pHIV-CAT, it appears to utilize a
different functional mechanism from that used by the other
herpesvirus trans-activators.
The exact mechanism by which the EBV BamHI MLFJ
gene product trans-activates pHIV-CAT is still unclear. The
finding that the HIV tat-responsive sequence is not essential
for trans-activation by EBV suggests that the BamHI MLFJ
is likely to function by a mechanism different from that of the
HIV tat. The HIV upstream negative regulatory element is
also dispensable for the EBV trans-activating effect (S.K.,
unpublished results), whereas the pCAT3M plasmid alone
(which contains no HIV promoter sequences) is no longer
trans-activated by BamHI MLFJ. The EBV trans-activator
could function at least partly by increasing the rate of
pHIV-CAT transcription, since it produces an increase in
the level of pHIV-CAT mRNA. Likewise, increased stabi-
lization of mRNA could also account for this observed
increase in pHIV-CAT mRNA. On the other hand, the
increase in CAT protein out of proportion to the mRNA
invokes an additional mechanism, such as increased trans-
lational efficiency of pHIV-CAT mRNA or increased stabil-
ity of the CAT protein itself. We think it very unlikely that
this greater increase in CAT protein stimulation versus CAT
RNA is artifactual and secondary to instability of CAT
mRNA, since in our hands two other trans-activating genes
(the human cytomegalovirus immediate-early gene and the
EBV BZLF1 immediate-early gene) have been shown to
function entirely at the level of increased mRNA using an
identical system. (S.K., unpublished data; ref. 32).
Since patients with AIDS have an increased incidence of
EBV-infected lymphomas (33, 34), this raises the possibility
that HIV-encoded gene products might also affect EBV
molecular processes. We have fused a number of promoters
from different classes of EBV genes to the bacterial CAT
gene. To date, however, we have been unable to demon-
strate activation of any EBV promoter by HIV gene prod-
ucts, including tat (S.K., unpublished results).
The biological relevance of the molecular interaction be-
tween EBV and HIV remains to be determined. A priori, one
might expect that the ability of the EBV BamHI M immedi-
ate-early gene to increase the level of gene expression ofHIV
could result in increased virus production. In many HIV-
infected individuals, the HIV genome is integrated within the
host-cell DNA but is not actively producing infectious virus.
The exposure of the HIV genome to the EBV BamHI MLF1
gene product might result in increased levels of viral gene
products (including tat) and consequently more virus produc-
tion. However, any effect of EBV on HIV replication would
be limited to B cells (and perhaps epithelial cells). Given the
ability of HIV to infect a number of different cell types (in
particular, the helper T cell), the clinical relevance of the
HIV/EBV interaction has yet to be established.
It is now known that at least two HIV gene products other
than tat are also important in HIV regulation. The HIV gene
art (or trs) appears to be required for the synthesis of the gag
and env proteins (10, 35). art may function by relieving an
inhibition to expression of the gag and env genes (35).
Another HIV gene product, termed 3'orf (or orfB), may
function to promote viral latency, since deletions in the 3'orf
consistently result in more viral replication than occurs with
wild-type virus (36, 37). The posttranscriptional effect of the
EBV trans-activator BamHI MLFI might affect certain of
these HIV proteins more than others. In addition, EBV might
increase the 3'orf gene product to the extent that HIV
replication might actually be decreased. In any event, the
biologic interactions between HIV and EBV are likely to be
important since these two viruses commonly coexist within
the human host, which may allow one virus to affect the
pathogenesis of the other.
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